Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

Conclusions Differential DNA methylation at the PPAR promoter can be detected within the pool of cell-free DNA of human plasma. With further validation, plasma DNA methylation of PPAR could potentially be used to non-invasively stratify liver fibrosis severity in patients with NAFLD. Plasma DNA methylation signatures reflect the molecular pathology associated with fibrotic liver disease.
Source: Gut - Category: Gastroenterology Authors: Tags: Open access Hepatology Source Type: research

Related Links:

Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Source Type: research
Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Hepatocellular carcinoma (HCC) has been increasing in incidence and prevalence for more than 30 years. As hepatologists have become more adept at treating underlying liver disease and cirrhosis, patients with cirrhosis are living longer, and with longer duration of cirrhosis comes an increased risk of HCC development. Cirrhosis is the underlying disease in most patients with HCC, although around 10% of HCC occurs without cirrhosis, often in the setting of chronic hepatitis B infection. Unfortunately, even with improving treatments for viral hepatitis, cirrhosis has continued to increase worldwide, due to the epidemic of no...
Source: Clinics in Liver Disease - Category: Gastroenterology Authors: Tags: Preface Source Type: research
ra Florea The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in the general population prompts for a quick response from physicians. As NAFLD can progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC), new non-invasive, rapid, cost-effective diagnostic methods are needed. In this review, we explore the diagnostic performance of ultrasound elastography for non-invasive assessment of NAFLD and NAFLD-related HCC. Elastography provides a new dimension to the conventional ultrasound examination, by adding the liver stiffness quantification in the diagnostic algorithm. Whilst the m...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionOur findings revealed that miR ‐34a was upregulated in a high‐fat environment in the liver, and induced hepatocyte senescence by targeting CDK6. The miR‐34a‐CDK6 signaling axis may promote NAFLD development in a high‐fat environment and therefore represents a potential target for NAFLD therapy.This article is protected by copyright. All rights reserved
Source: Molecular Nutrition and Food Research - Category: Food Science Authors: Tags: Research Article Source Type: research
Authors: Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK Abstract Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis (NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood, but lipidomics approach revealed that the hepatic lipidome is extensively altered in the setting of steatosis and steatohepatitis and these alterations correlate with disease progression. Recent data suggest that both quantity and...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Abstract Systemic lupus erythematosus (SLE), a multisystem autoimmune inflammatory disease, may involve any organs, including the liver. Liver involvement in SLE is not part of the American College of Rheumatology criteria and is relatively rare. Liver disease is usually mild, manifesting as subtle elevation of liver enzymes. Jaundice and hepatomegaly can be seen in some patients; advanced liver disease with cirrhosis is extremely rare. Precise pathology remains obscure. SLE may cause non-specific changes, including hepatocellular, cholestatic, or vascular changes. Alcohol, drugs, viral infections, metabolic disor...
Source: Scandinavian Journal of Rheumatology - Category: Rheumatology Authors: Tags: Scand J Rheumatol Source Type: research
Authors: Tan PO, Mustaffa N, Tan SS, Lee YY Abstract Globally, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly and constitutes a significant healthcare burden due to associated complications including hepatic (cirrhosis and hepatocellular cancer) and non-hepatic (cardiovascular deaths) disorders. It is closely linked to insulin resistance and metabolic syndrome but moderate alcohol consumption frequently coexists. Recently, genetic polymorphisms were implicated in the development of non-obese NAFLD. Apart from liver biopsy, in order to assess for steatosis, fibrosis and non-alcohol...
Source: Journal of the Royal College of Physicians of Edinburgh - Category: General Medicine Tags: J R Coll Physicians Edinb Source Type: research
Authors: Shao M, Ye Z, Qin Y, Wu T Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and can lead to liver cirrhosis or liver cancer in severe cases. In recent years, the incidence of NAFLD has increased substantially. The trend has continued to increase and has become a key point of concern for health systems. NAFLD is often associated with metabolic abnormalities caused by increased visceral obesity, including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and systemic microinflammation. Therefore, the pathophysiological mechani...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
We read with great interest the paper published in Journal of Hepatology by Eslam et  al.,1 which we feel is particularly relevant to hepatologists who manage patients with non-alcoholic fatty liver disease (NAFLD), a disease now advocated to be redefined as metabolic dysfunction-associated fatty liver disease (MAFLD). With the rising prevalence of MAFLD, we increasingly encounter patients with heterogeneous clinical profiles – from simple excessive hepatic fat detected on imaging, to steatohepatitis or even cirrhosis.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
More News: Alcoholism | Cirrhosis | Fatty Liver Disease (FLD) | Gastroenterology | Genetics | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pathology | Study | Urology & Nephrology